Neonatal exposure to MK801 induces structural reorganization of the central nervous system

NeuroReport

Volumn 17, Issue 8, 2006, Pages 779-783

  Lema Tomé, Carla M ^a,b   Nottingham, Charles U ^a   Smith, Chelsey M ^a   Beauchamp, Amanda S ^a   Leung, Parkson W ^a   Turner, Christopher P ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoskeleton; Development; Glutamate; N methyl D aspartate; Rat; Synaptic proteins

Indexed keywords

CASPASE 3; CYTOSKELETON PROTEIN; DIZOCILPINE; GLUTAMIC ACID; MICROTUBULE ASSOCIATED PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN REGION; CELL INTERACTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SOMATOSENSORY CORTEX; TRAUMATIC BRAIN INJURY;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BRAIN; CASPASE 3; CASPASES; CYTOSKELETON; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; MICROTUBULE-ASSOCIATED PROTEINS; NERVE NET; NEURAL PATHWAYS; NEURONAL PLASTICITY; NEURONS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SOMATOSENSORY CORTEX; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TAU PROTEINS;

EID: 33744464757     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000220133.32091.d6     Document Type: Article

References (26)

1. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330:681-690.
2. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999; 122:593-624.
3. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999; 45:1099-1119.
4. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 1986; 43:114-124.
5. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52:998-1007.
6. Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA 1995; 92:9077-9081.
7. Cull-Candy S, Brickley S,Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11:327-335.
8. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283:70-74.
9. Turner CP, Pulciani D, Rivkees SA. Reduction in intracellular calcium levels induces injury in developing neurons. Exp Neurol 2002; 178:21-32.
10. Wang C, Anastasio N, Popov V, Leday A, Johnson KM. Blockade of N-methyl-D-aspartate receptors by phencyclidine causes the loss of corticostriatal neurons. Neuroscience 2004; 125:473-483.
11. Wang CZ, Johnson KM. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 2005; 81:284-292.
12. Harris LW, Sharp T, Gartlon J, Jones DN, Harrison PJ. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 2003; 18:1706-1710.
13. Harrison PJ, Law AJ, Eastwood SL. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 2003; 1003:94-101.
14. Whitaker-Azmitia PM, Borella A, Raio N. Serotonin depletion in the adult rat causes loss of the dendritic marker MAP-2. A new animal model of schizophrenia? Neuropsychopharmacology 1995; 12:269-272.
15. Arnold SE, Lee VM, Gur RE,Trojanowski JQ. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci USA 1991; 88:10850-10854.
16. Rametti A, Esclaire F, Yardin C, Terro F. Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 2004; 279:54518-54528.
17. Buddle M, Eberhardt E, Ciminello LH, Levin T, Wing R, DiPasquale K, et al. Microtubule-associated protein 2 (MAP2) associates with the NMDA receptor and is spatially redistributed within rat hippocampal neurons after oxygen-glucose deprivation. Brain Res 2003; 978:38-50.
18. Fatemi SH, Earle JA, Stary JM, Lee S, Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 2001; 12:3257-3262.
19. Vogeley K, Jung V, Kawasaki E, Hutte H, Tepest R, Zilles K, et al. Cytoarchitectural alterations and increased SNAP25 density in the prefrontal region suggest hyper-innervation in schizophrenia. Schizophr Res 1999; 36:85-86.
20. Thompson PM, Sower AC,Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998; 43:239-243.
21. Schroder J, Essig M, Baudendistel K, Jahn T, Gerdsen I, Stockert A, et al. Motor dysfunction and sensorimotor cortex activation changes in schizophrenia: a study with functional magnetic resonance imaging. Neuroimage 1999; 9:81-87.
22. Mattson MP. Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 1992; 27:29-49.
23. Paxinos G. The rat nervous system. San Diego: Elsevier; 2004.
24. Jones LB, Johnson N,Byne W. Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Res 2002; 114:137-148.
25. Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005; 80:591-596.
26. Law AJ, Hutchinson LJ, Burnet PW, Harrison PJ. Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex. J Neurosci Res 2004; 76:376-382.